Nakamura K, Aoshima M, Tani M, Kato T, Fugita M, Kimura A, Hasegawa T, Akiyama K, Makino I
Second Department of Internal Medicine, Asahikawa Medical College.
Nihon Shokakibyo Gakkai Zasshi. 1992 Dec;89(12):2762-70.
Effect of ursodeoxycholic acid (600 mg/day 12 weeks) on liver function tests and bile acid metabolism were investigated in 6 patients with compensatory liver cirrhosis (CLC) and 6 with chronic active hepatitis (CAH). Serial determination of serum GOT, GPT and gamma-GTP after the initiation of UDCA revealed significant reduction in mean levels of these enzymes after 4 weeks, and further improvement was observed at the end of the 12-weeks treatment regimen (CLC: 79.3%, 81.1%, 51.5% of initial values, respectively, CAH: 61.2%, 59.3%, 42.8%). On the other hand, after UDCA administration, serum total bile acid increased and UDCA became the predominant bile acid in CLC and CAH patients. Other endogenous bile acids decreased in both groups, but reduction rate of serum chenodeoxycholic acid level in CLC was smaller than that in CAH group (CLC: 86.1% of initial values, respectively, CAH: 54.2%). During UDCA treatment, apparent side effect was not observed. We suggest that UDCA administration might constitute effective treatment for compensatory liver cirrhosis as well as chronic hepatitis.
研究了熊去氧胆酸（600毫克/天，共12周）对6例代偿性肝硬化（CLC）患者和6例慢性活动性肝炎（CAH）患者肝功能检查及胆汁酸代谢的影响。开始使用熊去氧胆酸后，连续测定血清谷草转氨酶（GOT）、谷丙转氨酶（GPT）和γ-谷氨酰转肽酶（γ-GTP），结果显示4周后这些酶的平均水平显著降低，在12周治疗方案结束时进一步改善（CLC组：分别为初始值的79.3%、81.1%、51.5%；CAH组：分别为61.2%、59.3%、42.8%）。另一方面，给予熊去氧胆酸后，血清总胆汁酸升高，且熊去氧胆酸成为CLC和CAH患者中的主要胆汁酸。两组中其他内源性胆汁酸均减少，但CLC组血清鹅去氧胆酸水平的降低率小于CAH组（CLC组：分别为初始值的86.1%；CAH组：54.2%）。在熊去氧胆酸治疗期间，未观察到明显的副作用。我们认为，给予熊去氧胆酸可能是代偿性肝硬化以及慢性肝炎的有效治疗方法。
